Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Sound waves could speed brain bleed recovery in stroke patients

NCT ID NCT07246473

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a non-invasive ultrasound device can safely help clear blood clots in the brain after a hemorrhagic stroke. About 86 adults with small-to-moderate brain bleeds will receive either standard care plus ultrasound or standard care alone. The main goal is to see if the ultrasound increases clot clearance within a week.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 86 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 to 80 years; * Spontaneous intracerebral hemorrhage (ICH); * Supratentorial ICH; * Hematoma volume \<30 mL (calculated using the ABC/2 method); * Glasgow Coma Scale (GCS) score \>9 at randomization; * Time from onset to randomization: 48-72 hours; * Patient and/or legal representative provides informed consent. Exclusion Criteria: * Intracerebral hemorrhage attributed to other causes (e.g., cerebral aneurysm, cerebrovascular malformation, brain tumor, cerebral venous sinus thrombosis, hemorrhagic transformation of ischemic stroke, head trauma, anticoagulation therapy, hematologic disorders). * Hemorrhage located in the infratentorial region. * Hemorrhage confined primarily to the ventricular system. * Clinical signs or symptoms suggestive of brain herniation (e.g., progressive decline in level of consciousness, diminished or absent pupillary light reflexes, bilateral pyramidal signs). * Severe cardiac dysfunction (NYHA Class III or IV). * High-risk chronic arrhythmias (e.g., sick sinus syndrome, second- or third-degree atrioventricular block, bradycardia-related syncope without pacemaker implantation). * Severe hepatic impairment defined as ALT \>2x ULN or AST \>2x ULN (ULN = Upper Limit of Normal). * Severe renal impairment defined as serum creatinine \>1.5x ULN. * History of severe asthma or chronic obstructive pulmonary disease (COPD). * History of coagulopathy or systemic bleeding disorder. * Leukopenia (\<2 × 10⁹/L) or thrombocytopenia (\<100 × 10⁹/L). * Patients scheduled for surgical intervention (including, but not limited to, hematoma evacuation \[minimally invasive or conventional\], decompressive craniectomy, hematoma aspiration, or external ventricular drainage) prior to the first dose of study treatment. * Pre-stroke modified Rankin Scale (mRS) score \>2. * Presence of other severe disease resulting in a life expectancy of less than 1 year. * Inability to understand the study procedures and/or complete follow-up due to psychiatric illness, cognitive impairment, or emotional disorders. * Women who are pregnant or lactating. * Participation in another clinical trial within the past 3 months or current participation in another clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Intracerebral hemorrhage are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beijing Fengtai You'anmen Hospital

    RECRUITING

    Beijing, Beijing Municipality, China

  • Beijing Tiantan Hospital of Capital Medical University

    RECRUITING

    Beijing, Beijing Municipality, China

  • The First Affiliated Hospital of Wannan Medical University

    NOT_YET_RECRUITING

    Wuhu, Anhui, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.